Although skin is the largest organ of the human body, cutaneous drug metabolism is often overlooked, and existing experimental models are insufficiently validated. This proof-of-concept study investigated phase II biotransformation of 11 test substrates in fresh full-thickness human skin explants, a model containing all skin cell types. Results show that skin explants have significant capacity for glucuronidation, sulfation, N-acetylation, catechol methylation, and glutathione conjugation. Novel skin metabolites were identified, including acyl glucuronides of indomethacin and diclofenac, glucuronides of 17b-estradiol, N-acetylprocainamide, and methoxy derivatives of 4-nitrocatechol and 2,3-dihydroxynaphthalene. Measured activities for 10 mM substrate incubations spanned a 1000-fold: from the highest 4.758 pmol·mg skin -1 ·h -1 for p-toluidine N-acetylation to the lowest 0.006 pmol·mg skin -1 ·h -1 for 17b-estradiol 17-glucuronidation. Interindividual variability was 1.4-to 13.0-fold, the highest being 4-methylumbelliferone and diclofenac glucuronidation. Reaction rates were generally linear up to 4 hours, although 24-hour incubations enabled detection of metabolites in trace amounts. All reactions were unaffected by the inclusion of cosubstrates, and freezing of the fresh skin led to loss of glucuronidation activity. The predicted whole-skin intrinsic metabolic clearances were significantly lower compared with corresponding whole-liver intrinsic clearances, suggesting a relatively limited contribution of the skin to the body's total systemic phase II enzymemediated metabolic clearance. Nevertheless, the fresh full-thickness skin explants represent a suitable model to study cutaneous phase II metabolism not only in drug elimination but also in toxicity, as formation of acyl glucuronides and sulfate conjugates could play a role in skin adverse reactions. dx.doi.org/10.1124/dmd.114.060350. s This article has supplemental material available at dmd.aspetjournals.org.
Introduction
With 1-2 m 2 of surface area (Verbraecken et al., 2006) and 2-4 kg of total body weight (Brown et al., 1997) , human skin is often exposed to therapeutic drugs, cosmetic ingredients, and environmental xenobiotics, either after topical or transdermal administration. In addition, many systemically administered drugs distribute into the skin, with local exposure approaching (Klimowicz et al., 1988; Borg et al., 1999; Krishna et al., 2010) , or sometimes even exceeding, corresponding plasma levels (Zucchi et al., 2001; Brunner et al., 2002) . As a result, cutaneous drug metabolism is relevant for pharmacotherapy, both from the perspectives of metabolic elimination and activation of prodrugs, as well as the formation of reactive metabolites that may cause skin toxicity (Sharma et al., 2013) . Despite this potential importance, cutaneous drug metabolism is generally overlooked and rarely discussed during drug development. A better understanding of skin metabolism could also close the general in vitro-in vivo extrapolation gap for drugs where extensive extrahepatic metabolic clearance is suspected (Hiraoka et al., 2005; Gundert-Remy et al., 2014) .
Drug metabolism is often a two-step process. In the first phase, compounds undergo reactions of oxidoreduction and hydrolysis, introducing or exposing nucleophilic groups; in the second phase, nucleophilic groups are conjugated with an endogenous molecule, such as glucuronic acid or glutathione, yielding hydrophilic and easily excretable drug conjugates with often diminished pharmacological activity. This study focused on activities of cutaneous phase II metabolic enzymes. A literature survey suggested that mRNA expression of phase II metabolic enzymes is higher than expression of corresponding phase I enzymes in human skin (Luu-The et al., 2009; Hu et al., 2010; van Eijl et al., 2012) . Numerous detected cutaneous transferases (Table 1) , namely UDP-glucuronosyltransferases (UGTs), sulfotransferases (SULTs), N-acetyltransferases (NATs), catechol-O-methyltransferase (COMT), and glutathione-S-transferases (GSTs), indicate a potentially significant role of the human skin in metabolic elimination and detoxification.
Despite the reports of gene expression (Table 1) , functional data such as enzymatic activities are largely missing, especially with the fresh human skin explants. Table 2 summarizes literature reports of phase II metabolic activities detected in different skin models. Most of the studies were performed with a single test compound and with experimental models that do not reflect the full complexity of the human skin-for example, isolated keratinocytes or subcellular fractions. Moreover, since skin is a fibrous tissue that is notably more difficult to homogenize than liver, preparation of skin subcellular fractions may reduce enzyme activities below the detection limits. Use of three-dimensional reconstructed skin models and immortalized cell lines (e.g., HaCaT cells) raises concerns of altered gene expression, even if existing studies are mostly encouraging (Bonifas et al., 2010b; Jackh et al., 2011; Gotz et al., 2012) . Skin explants were rarely used in the past and mostly dermatomed to thickness below 500 mm (Ademola et al., 1993; Moss et al., 2000; Goebel et al., 2009; Zalko et al., 2011) , thus minimizing the potential metabolic contributions of skin dermis. Taken together, difficulties in accessing fresh human tissue, lack of alternative and simpler model validation against the full-thickness human skin, limited selection of test substrates, and potential enzyme inactivation in skin subcellular Dooley et al., 2000; Higashi et al., 2004; Luu-The et al., 2009; Hu et al., 2010; Kushida et al., 2011 NAT NAT1 a , NAT2 Luu-The et al., 2009 Bonifas et al., 2010a; Hu et al., 2010; van Eijl et al., 2012 COMT Single human gene is detected Luu-The et al., 2009; Hu et al., 2010; van Eijl et al., 2012 GST a a , m a , P a , Q, z, V Blacker et al., 1991; Raza et al., 1991; Luu-The et al., 2009; Hu et al., 2010; van Eijl et al., 2012 a Enzymes with higher reported expression. fractions all contribute to limited knowledge about phase II metabolism in the human skin.
To address these challenges, we investigated activities of UGTs, SULTs, NATs, COMT, and GSTs in fresh full-thickness human skin explants. This experimental model was selected based on the presence of all skin cell types, such as keratinocytes, Langerhans cells, Merkel cells, and melanocytes in the epidermis, as well as fibroblasts and macrophages in the dermis (Lebonvallet et al., 2010) . Therefore, as an advantage over many simpler experimental models, full-thickness skin explants show enzymatic activities of both skin epidermis and dermis. With an aim of preserving skin's maximal metabolic capacity, special attention was paid to freshness and viability of the explant culture. To produce robust results and shed light on interindividual variability, 11 substrates of different physicochemical properties ( Fig. 1) were individually assayed in a minimum of three different skin donors. To gain better understanding of the skin's relative contribution to the body's total systemic phase II enzyme-mediated metabolic clearance, metabolic activities measured in skin explants were scaled up to apparent wholeskin intrinsic clearances (CL int;skin ) and compared with corresponding whole-liver intrinsic clearances (CL int;liver ). The results presented here significantly deepen our knowledge about cutaneous phase II metabolism, and open new research directions toward understanding not only metabolic elimination but also the toxicological impact of new drugs and cosmetic products.
Materials and Methods

Reagents and Chemicals
Belzer UW cold storage solution (organ preservation medium) was obtained from Bridge to Life (Columbia, SC). Cytotoxicity detection kit plus, a lactate dehydrogenase release assay, was acquired from Roche (Basel, Switzerland). Penicillin-streptomycin-glutamine (10,000 U·ml -1 penicillin, 10,000 mg·ml -1 streptomycin, 29.2 mg·ml -1 glutamine; used as 100-fold dilution) was purchased from Life Technologies (Carlsbad, CA). Williams' E medium (1.8 mM Ca 2+ , no glutamine), dimethylsulfoxide (DMSO, $99.7%), insulin from bovine pancreas ($27 USP units·mg -1 ), hydrocortisone (suitable for cell culture), formic acid ($98%), 4-methylumbelliferone ($98%), 4-methylumbelliferone-b-D-glucuronide hydrate ($98%), 4-nitrophenyl b-D-glucuronide ($98%), 17b-estradiol ($98%), 17b-estradiol-17-b-D-glucuronide sodium salt ($98%), 17b-estradiol-3-b-Dglucuronide sodium salt ($98%), 17b-estradiol-3-sulfate sodium salt ($93%), minoxidil ($99%), minoxidil sulfate ($98%), p-toluidine (99.7%), 49-methylacetanilide (99%), 2,3-dihydroxynaphthalene ($98.0%), 3-methoxy-2-naphthol (97%), 4-nitrocatechol (97%), 4-nitroguaiacol (97%), 1-chloro-2,4-dinitrobenzene (CDNB; $99%), procainamide hydrochloride ($99%), N-acetylprocainamide hydrochloride ($99%), UDP-a-D-glucuronic acid trisodium salt (UDPGA; 98-100%), adenosine 39-phosphate 59-phosphosulfate lithium salt hydrate (PAPS; $60%), S-(59-adenosyl)-L-methionine chloride dihydrochloride (SAM; $75%), D-saccharic acid 1,4-lactone monohydrate (D-saccharolactone; $98%), acetyl coenzyme A sodium salt (AcCoA; $93%), and in vitro toxicology assay kit [3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) based] were purchased from Sigma-Aldrich (Buchs, Switzerland). Indomethacin, indomethacin acyl-b-D-glucuronide, diclofenac sodium salt, diclofenac acyl-b-D-glucuronide, Fig. 1 . Chemical structures of the compounds tested in this study. Location of metabolic reaction is indicated with a dotted circle or arrow. Observed phase II biotransformation is indicated below the substrate's name. Physicochemical properties of the compounds are presented in Table 5 . Phase II metabolic activities measured in the fresh full-thickness human skin explants are presented in Fig. 3 and Table 6. triclosan O-sulfate sodium salt, triclosan O-b-D-glucuronide sodium salt, S-(2,4dinitrophenyl)-glutathione, and 4-hydroxycarbazeran were acquired from Toronto Research Chemicals (Toronto, ON, Canada). Triclosan was purchased from Molekula (Munich, Germany). Organic solvents of liquid chromatography-mass spectrometry or higher purity grade were used in this study. Stock solutions of the test substrates were prepared in DMSO (10 mM) and then stored at -20°C until use. Stock solution of cosubstrates (UDPGA, PAPS, SAM, and AcCoA) and D-saccharolactone were prepared in purified water (50 mM) and used immediately in the assay.
Materials for Tissue Explant Culture
Stericup filter units (0.22 mm) and receiver flasks were purchased from Millipore (Billerica, MA). Sterile biopsy explant tools, 4 mm in diameter, were ordered from either Acuderm (Fort Lauderdale, FL) or Stiefel (GlaxoSmithKline company, Research Triangle Park, NC). Falcon 24-well plates were purchased from Corning (Tewksbury, MA).
Skin Explants Culture
Healthy full-thickness human skin was obtained under informed consent from individuals undergoing plastic or reconstructive surgery at the Institute for Plastic, Reconstructive, Aesthetic and Hand Surgery, Basel University Hospital (Basel, Switzerland). The study protocol was approved by the local ethics committee of Basel, Switzerland, and the study was performed in accordance with the Declaration of Helsinki (1964 and subsequent revisions). In total, skin samples from 17 individuals were collected (donors' demographic information is presented in Table 3 ). Skin donors were predominantly female Caucasians (87.5%), although two male subjects were also included in the study (Table 3) . Donor age ranged from 35 to 73 years, with a median age of 58 years. Depending on the donor, skin samples were taken from different anatomic regions, namely abdomen (8 donors), breast (3 donors), inguinal area (groin; 2 donors), arm (2 donors), thigh (1 donor), and eyelids (1 donor). To preserve viability and metabolic capacity of the tissue, excised human skin was immediately submerged in the Belzer UW organ preservation solution supplemented with penicillin (100 U·ml -1 ) and streptomycin (100 mg·ml -1 ), a specialized medium commonly used for solid organ transplantation (Sollinger et al., 1989) . Skin was transported to our laboratories at 4°C, generally within 30-90 minutes from the time of surgical excision.
After arrival, skin tissue was handled within a laminar flow hood and processed using sterile dissection tools. Adipose tissue and hypodermis were removed and, depending on the anatomic region and individual sample, dermis was trimmed with curved surgical scissors to achieve maximal overall skin thickness of approximately 3 mm. Skin thickness varied based on anatomic region and individual characteristics of the donor (,1 mm for eyelids, 1-2 mm for breast and inguinal, 2-5 mm for abdomen and thigh skin). Cylindrical skin explants, 4 mm in diameter (12.5 mm 2 ), were prepared with a sterile biopsy tool and immediately placed in prewarmed Williams' E medium supplemented with insulin (10 mg·ml -1 ), hydrocortisone (10 ng·ml -1 ), and penicillin-streptomycinglutamine (100 U·ml -1 of penicillin; 100 mg·ml -1 of streptomycin; 2 mM L-glutamine) (Lu et al., 2007) . Medium pH value was 7.4, culturing temperature was 37°C, incubator humidity was 90%, and CO 2 content was 5%. Skin explant viability after 24 hours of culture was confirmed by histology (hematoxylin and eosin staining), lactate dehydrogenase release, and MTT viability assays. Viability assays were performed according to the manufacturer's protocols. Skin explant preparation procedure, composition and volume of the culturing medium, calcium concentration, and the use of antibiotics were optimized prior to metabolic experiments (Litherland et al., manuscript in preparation) .
Drug Metabolism Assays
Skin explants were incubated in 0.5 ml of Williams' E medium (pH 7.4) spiked with 10 mM test substrate (final DMSO concentration was 0.1%). Incubations were performed for 15-24 hours, depending on the individual skin sample assayed. Time-course assays were performed in the interval from 1 to 24 hours. Enzyme kinetics assay of 4-methylumbelliferone glucuronidation was performed with substrate concentrations from 1 to 150 mM and incubation time of 3 hours. To achieve maximal exposure of skin to probe substrates, skin explants were freely floating in the medium with epidermis facing the air-liquid interface. After incubation time, both skin explants and corresponding incubation media were placed in centrifuge tubes and snap-frozen in liquid nitrogen. Until analysis, samples were stored at -80°C. All incubations were performed in duplicate.
To efficiently extract metabolites from the skin explants, skin tissue was cryofractured with a cryoPREP Impactor (Covaris, Woburn, MA). Skin explants were placed in TT05XT tissue tubes (Covaris), cooled in liquid nitrogen, and then cryofractured once with cryoPREP Impactor (impact strength 2). Cryofractured skin samples were transferred to centrifuge tubes filled with lysing matrix D (MP Biomedicals, Santa Ana, CA), 1 ml of 70% acetonitrile was added (v/v), and samples were further homogenized using a FastPrep instrument (MP Biomedicals; agitation speed was 4.0 m·s -1 ; three cycles of 20 seconds each). Corresponding skin incubation medium was directly mixed with acetonitrile (30:70 v/v) and vortexed for 1 minute. All samples were placed overnight at -20°C, centrifuged at 30,000g for 30 minutes, and aliquots of the supernatants were spiked with suitable internal standard. Samples were evaporated to dryness (in vacuum or under nitrogen stream) and then reconstituted with mobile phase. Negative control samples, probe substrate in blank medium, and skin explants without probe substrate were analyzed in parallel.
Analytics
Extracted metabolites were detected and quantified using a Quattro Ultima triple-quadruple mass spectrometer equipped with an electrospray ion source Demographics of skin donors that participated in the study Out of 16 donors in total, 87.5% were female and 12.5% were male. See Fig. 3 and Table 6 (Waters, Milford, MA) , coupled with an Agilent 1100 capillary high-performance liquid chromatography pump (Agilent, Santa Clara, CA) and a CTC Pal autosampler (CTC Analytics, Zwingen, Switzerland). Metabolite quantification was performed in multiple-reaction monitoring mode, and resulting chromatograms were analyzed with MassLynx 4.1 software (Waters). Since 3-methoxy-2naphthol, a methylated metabolite of 2,3-dihydroxynaphthalene, is highly fluorescent and poorly ionizable, the analysis was performed using an Agilent 1100 high-performance liquid chromatography system equipped with a fluorescence detector. Fluorescence data were analyzed with ChemStation B.04.02 software (Agilent). For all used analytical methods, the limits of detection and quantification were estimated based on signal-to-noise ratios of 3 and 10, respectively. Standard curves were generally prepared in the concentration range of 1-1000 nM. Further details of the analytical methods are presented in Table 4 .
Data Analysis
Amounts of metabolites quantified were normalized to average skin explant weight (for the individual donor) and total media volume (500 ml). To calculate the total amount of metabolite formed in the incubation, we summed the amounts quantified in skin explant extract and corresponding medium extract. Due to difficulties in quantitative extraction of proteins from the skin tissue, activities measured in skin explants are presented as picomole of metabolite formed per milligram of skin tissue (not milligram of protein) and hours of incubation time (pmol·mg skin -1 ·h -1 ). Physicochemical properties of the test substrates were calculated using ACD Laboratories (Toronto, ON, Canada) or ChemAxon (Budapest, Hungary) software. Figure preparation, statistical tests, and curve fitting were performed with GraphPad Prism 6.02 for Windows (GraphPad Software Inc., San Diego, CA).
Prediction of Skin Clearances and Comparison with Liver Clearances
Intrinsic Clearances Derived from Skin Explants. Applying Michaelis- and [S] represent the metabolic activity of the skin explant (pmol·min -1 , average skin explant weight for individual donor is taken into account), the maximum reaction velocity (pmol·min -1 ), the affinity constant (mM), and the concentration of substrate at which the activity was measured (mM), respectively] and assuming an absence of unspecific intracellular binding events, the maximal intrinsic metabolic skin clearance (at [S] , , K m , ml·min -1 ) from a singleconcentration metabolism assay in the skin explants can be calculated as follows:
Since reactions of sulfation, N-acetylation, catechol methylation, and glutathione conjugation showed nonlinearity over 24 hours of incubation in skin explants (see Fig. 4 ), the CL int;skin values for these reactions were multiplied by a correction factor derived from the time-course assays as follows:
where CL 4h int;skin and CL 24h int;skin are the intrinsic skin clearances calculated after 4 and 24 hours of incubation, respectively. Accordingly, v 4h and v 24h are the enzyme activities measured after 4 and 24 hours of incubation [calculated correction factors: glucuronidation 1.00 (linear); catechol methylation 1.61; N-acetylation 1.73; glutathione conjugation 2.75; sulfation 2.83]. The in vitro   TABLE 4 Analytical methods used for separation, detection, and quantification of metabolites formed in the human skin explants For all methods, eluents A and B were 0.1% formic acid in water and 0.1% formic acid in acetonitrile, respectively. Analytes were separated on the following high-performance liquid chromatography (HPLC) columns: Agilent StableBond C18 (column A: 50 Â 1.0 mm; column B: 150 Â 1.0 mm; 3.5 mm particle size; Agilent), Phenomenex Luna pentafluorophenyl (column C: 150 Â 1.0 mm, 3 mm particle size; Phenomenex, Torrance, CA), or Waters SunFire C18 column (column D: 150 Â 2.1 mm, 3.5 mm particle size; Waters). Eluent flow rates were 0.1 and 0.3 ml/min for 1.0-and 2.1-mm diameter analytical columns, respectively. Column temperature was 40°C and injection volume was 10 ml. intrinsic clearances can be scaled to in vivo (whole skin) by applying either a skin surface or skin weight scaling factor. Assuming that average surface areas of whole human skin and prepared skin explants are 2 Â 10 6 mm 2 and 12.5 mm 2 , respectively, estimated skin surface scaling factor is 160,000-fold. Corresponding skin weight scaling factor ranges from 74,000-to 260,000-fold, depending on the average weight of the skin explants prepared from individual donors [average skin explant weight ranged from 10 to 35 mg; assumed average total skin weight was 2.6 kg for a 70-kg individual (Brown et al., 1997) ].
Since prepared skin explants had a well defined surface area (12.5 mm 2 ), but highly variable weight dependent on skin anatomic region and individual donor, skin surface scaling factor was used in calculations as a more robust parameter. Intrinsic Clearances Derived from Liver Fractions. The in vitro intrinsic clearances for the corresponding phase II reactions in human liver fractions (microsomes, cytosol, or S9), CL int;liver (ml·min -1 ·mg -1 ), were calculated from enzyme kinetics parameters reported in the literature (Supplemental Table 1 ). For reactions following Michaelis-Menten enzyme kinetics, intrinsic clearances were calculated as described earlier (CL int;liver ¼ V max =K m ). In the case of Hilltype reactions, the in vitro clearance of the maximally activated enzyme was calculated as described elsewhere ½CL int;liver ¼ Vmax S50 ðh 2 1Þ hðh 2 1Þ 1=h , where h is the Hill slope of the fitted curve and S 50 is the concentration of substrate at V max /2 (Houston and Galetin, 2008) ]. In the case of multiple literature reports, average CL int;liver values were used (see Supplemental Table 1 ). The intrinsic hepatic in vitro clearances were scaled up to a ml·min -1 ·kg -1 body weight basis as described previously (Camenisch and Umehara, 2012) . The following scaling factors from the literature were applied: 52.5 mg of protein/g of liver for liver microsomes (Iwatsubo et al., 1997) , 80.7 mg of protein/g of liver for cytosol (Houston and Galetin, 2008) , 121 mg of protein/g of liver for S9 fraction (Nishimuta et al., 2014) , and 25.7 g of liver/kg of body weight for the liver weight (Davies and Morris, 1993) .
Calculation of Systemic Organ Clearances. Applying the so-called well stirred model, and assuming instantaneous and homogenous drug distribution (i.e., no permeability limitation), the systemic in vivo clearances for any perfused organ in the absence of protein binding can be determined as follows (Ito and Houston, 2004) :
where Q is the organ blood flow [Q liver = 20.7 ml·min -1 ·kg -1 and Q skin = 4.3 7 ml·min -1 ·kg -1 (Davies and Morris, 1993) ]. Systemic organ clearances were calculated for average body weight of 70 kg.
Results
To investigate phase II metabolism in human skin, full-thickness skin explants were incubated with 11 test compounds of various physicochemical properties ( Fig. 1; Table 5 ). Test compounds were selected based on either good activity toward the target enzymes-for example, 4-methylumbelliferone for UGTs (Manevski et al., 2013) and 1-chloro-2,4-dinitrobenzene for GSTs (Habig et al., 1974 )-or relevance to pharmacotherapy (minoxidil, indomethacin, diclofenac, 17b-estradiol, triclosan) . Many of the test compounds are substrates for several individual enzymes within the single transferase family: for example, 4-methylumbelliferone (Manevski et al., 2013) , 17b-estradiol (Itäaho et al., 2008) , diclofenac (King et al., 2001; Kuehl et al., 2005) , and indomethacin (Kuehl et al., 2005) are glucuronidated by multiple UGTs; minoxidil is a substrate for several SULTs (Anderson et al., 1998) ; and 1-chloro-2,4-dinitrobenzene is metabolized by multiple GSTs (Hayes et al., 2005) . Since the stratum corneum may severely limit the skin permeation of topically administered drugs, test compounds were directly added to the incubation medium to maximize the tissue exposure. Due to limited availability and small size of the human skin samples, incubations were mainly performed only with a single substrate concentration of 10 mM. After 1-24 hours of incubation time, both skin explant and corresponding medium were analyzed for the presence of specific phase II metabolites. Histologic analysis of formalin-fixed paraffinembedded skin tissue, stained with hematoxylin and eosin, showed that skin explants kept normal morphology and viability at least for the first 24 hours (Fig. 2 ). All reactions were tested in three different skin donors, with the exception of 4-methylumbelliferone glucuronidation, minoxidil sulfation, p-toluidine N-acetylation, and 2,3-dihydroxynaphthalene methylation, which were assayed in skin explants from 13, 7, 5, and 5 individual donors, respectively.
Phase II Metabolic Activities in Human Skin Explants. Results show that human skin has a significant potential for glucuronidation, sulfation, N-acetylation, catechol methylation, and glutathione conjugation ( Fig. 3 ; Table 6 ). At least one phase II metabolite was detected for all different tested compounds, whereas 17b-estradiol and triclosan yielded both glucuronide and sulfate conjugates. To our best knowledge, this is the first report of indomethacin glucuronidation, diclofenac glucuronidation, 17b-estradiol 3-and 17-glucuronidation, procainamide N-acetylation, 4-nitrocatechol methylation, and 2,3-dihydroxynaphthalene methylation in the human skin.
Average activities for 10 mM incubations varied approximately 1000-fold, ranging from the highest, 4.758 pmol·mg skin -1 ·h -1 for p-toluidine N-acetylation, to the lowest, 0.006 pmol·mg skin -1 ·h -1 for 17b-estradiol 17-glucuronidation ( Fig. 3 ; Table 6 ). Importantly, for all phase II reactions, at least one representative compound had faster turnover: for example, rates higher than 1.0 pmol·mg skin -1 ·h -1 were measured for p-toluidine N-acetylation, 4-methylumbelliferone glucuronidation, 2,3-dihydroxynaphthalene methylation, and triclosan sulfation (Fig. 3A) . The rate of 1-chloro-2,4-dinitrobenzene glutathione conjugation was also high within the first hour of the incubation, but slowed down afterward. Significant metabolic turnover was confirmed by calculating the apparent substrate depletion during the experiment (Fig. 3B ). For p-toluidine, assuming that N-acetylation is the only metabolic pathway, up to 70% of substrate was consumed during 24 hours of incubation. On the other hand, reactions of minoxidil sulfation, procainamide N-acetylation, diclofenac glucuronidation, and 17b-estradiol glucuronidation on average consumed less than 1% of substrate in the reaction. Phase II metabolism in the skin explants also exhibited interindividual variability (Table 6 ). Variation between donors was the highest for 4-methylumbelliferone and diclofenac glucuronidation (up to 13-fold); moderate for 17b-estradiol 3-glucuronidation and 3-sulfation, triclosan glucuronidation, minoxidil sulfation, and 2,3-dihydroxynaphthalene methylation (3-to 5-fold); and lowest for p-toluidine and procainamide N-acetylation, triclosan sulfation, and 17b-estradiol 17-glucuronidation (1-to 2-fold). Higher interindividual variation observed in 4-methylumbelliferone and diclofenac glucuronidation might be due to an eyelid skin sample from a male individual (donor 18). Skin sample from this donor glucuronidated 4-methylumbelliferone and diclofenac at a rate that was approximately 3-fold faster than the corresponding average value. Since cutaneous glucuronidation of 4-methylumbelliferone was tested in skin explants from 13 individual skin donors, results also enabled insight into the relationship between glucuronidation rate and donor demographics. However, measured glucuronidation rates were not statistically significantly correlated with donors' age, smoking habits, or alcohol intake (data not shown).
Time Course of Phase II Metabolite Formation in Human Skin Explants. To determine the linearity of phase II metabolism in human skin explants, the time course of five representative reactions were tested, namely 4-methylumbelliferone glucuronidation, minoxidil sulfation, p-toluidine N-acetylation, 2,3-dihydroxynaphthalene methylation, and 1-chloro-2,4-dinitrobenzene glutathione conjugation (Fig. 4) . Glucuronidation rate was linear over 24 hours of incubation (Fig. 4A ), but reaction rates of minoxidil sulfation (Fig. 4B) , p-toluidine N-acetylation (Fig. 4C) , and 2,3-dihydroxynaphthalene methylation (Fig. 4D) started to decrease after about 4 hours. A similar trend was observed for 1-chloro-2,4dinitrobenzene glutathione conjugation (Fig. 4E) , where reaction decelerated after the first hour of incubation. These results indicate that activity rates for 24-hour incubations, expressed as pmol·mg skin -1 ·h -1 , are underestimated for N-acetylation, catechol methylation, sulfation, and glutathione conjugation. Since most reactions were linear up to 4 hours, incubations within this time window are more suitable for experiments in which linearity is important-for example, enzyme kinetic assays.
Distribution of formed phase II metabolites differed between the skin explant and corresponding incubation medium over time (Fig. 4) . Within initial time points (1-2 hours), compared with the surrounding medium, larger quantities of metabolites were observed in the skin explant. In contrast, at later time points (4-24 hours), most of the metabolites were found in the incubation medium. Considering that many phase II metabolites are hydrophilic and polar compounds, unlikely to cross the cell membrane passively, these results suggest that human skin actively excretes the newly formed phase II metabolites. Leakage from damaged cells into the medium over assay time, another hypothesis leading to predominantly extracellular localization of metabolites, was unsupported by the unaltered microscopic morphology of the skin explants during the 24-hour period of incubation (Fig. 2) .
Inclusion of Cosubstrates in Human Skin Explant Culture. In an effort to optimize incubation conditions for the maximal enzyme activities, we tested the effects of cosubstrate inclusion in the medium on activities of phase II metabolic reactions in human skin explants (Fig. 5 ). Addition of 1 mM UDPGA, PAPS, AcCoA, and SAM did not significantly enhance the reaction rates of glucuronidation, sulfation, N-acetylation, and catechol methylation, respectively. Similarly, the inclusion of 1 mM D-saccharolactone, an inhibitor of b-glucuronidase (Oleson and Court, 2008) , did not affect the glucuronidation rate of 4-methylumbelliferone. Since conjugation with glutathione may also proceed as a nonenzymatic reaction (Satoh, 1995) , the assays were not performed in a medium supplemented with glutathione.
Influence of Substrate Physicochemical Properties on Human Skin Phase II Metabolic Rates. To investigate whether physicochemical properties of the substrates influence phase II metabolic activities in human skin, we plotted log D (pH 7.4), molecular weight, solventaccessible surface area, and polar surface area against average measured metabolic rates (Fig. 6 ). Activities were generally higher for compounds with smaller molecular weight ( Fig. 6B ; one-phase decay fit; r 2 = 0.65), solvent-accessible surface area below 300 Å 2 (Fig. 6C ; one-phase decay fit; r 2 = 0.52), and polar surface area below 50 Å 2 (Fig. 6D ; one-phase decay fit; r 2 = 0.65). Activity correlations with substrates' log D at pH 7.4 ( Fig. 6A) and pK a or pK b (not shown) were inconclusive, perhaps due to the limited number of substrates tested.
Effects of Rapid Skin Freezing on Glucuronidation Activity in Human Skin Explants. To examine whether a freeze-thaw cycle influences the metabolic activity of human skin samples, we snap froze full-thickness human skin in liquid nitrogen, kept it frozen for 7 days at -80°C, thawed at room temperature, and then tested 4-methylumbelliferone glucuronidation. An MTT viability assay was also performed in parallel (Fig. 7) . In contrast to activities found in the fresh skin explants from the same donor (Fig. 3) , results showed that a single freeze-thaw cycle diminished the 4-methylumbelliferone glucuronidation below the detection limit (Fig. 7A ). Viability assay with MTT dye showed that remaining skin viability was below 10% of the control fresh sample (Fig. 7B) .
Skin and Liver Metabolism Comparison. To estimate the extent of skin metabolism and to compare it to the liver, measured activities in human skin and corresponding reactions in human liver were scaled up to in vivo intrinsic clearances as well as to the corresponding organ clearances (see Materials and Methods).
In-depth analysis revealed that the liver intrinsic clearances (CL int;liver ) for all tested compounds and reactions were significantly higher than the corresponding predicted skin values (CL int;skin ) (Fig.  8A) . The ratios between CL int;liver and CL int;skin ranged from 11-fold (17b-estradiol-3-sulfation) to more than 160,000-fold (diclofenac glucuronidation) ( Fig. 8B; Table 7 ). These large differences in intrinsic clearances evidently also translate into organ clearances. However, since liver organ clearances for a number of reactions are limited by the hepatic blood flow, whereas all skin organ clearances were below the skin blood flow, differences between liver and skin organ clearances are somewhat smaller (from 11-to 20,000-fold).
Discussion
Human skin is often exposed to therapeutic drugs and cosmetic ingredients, either after topical administration or due to distribution from the systemic circulation. Recent gene expression studies identified a number of transferases in the human skin (Table 1) , enzymes that are important for metabolic elimination and detoxification. Although useful for approximating the protein levels, studies of mRNA expression are often limited by poor correlation between measured mRNA levels and actual protein levels (Izukawa et al., 2009; Maier et al., 2009; Oda et al., 2012; Vogel and Marcotte, 2012) . Proteomic profiling may solve this problem, but a recent large study failed to detect UGTs and NATs in whole human skin (van Eijl et al., 2012) , despite previous reports of their activities (Table 2) . Cutaneous enzyme activities were rarely measured in the past, usually with a single substrate or in an experimental model that may poorly reflect the metabolic activity of the in vivo human skin-for example, skin microsomes or reconstructed threedimensional skin models (Table 2) . Skin explants were also used previously (Moss et al., 2000; Goebel et al., 2009; Zalko et al., 2011) , but dermatomed to 230-500 mM, effectively minimizing the possible contribution of skin dermis to drug biotransformation.
To contribute to a better understanding of phase II metabolism in human skin, we investigated the biotransformation of 11 test substrates Metabolic rates measured in human skin explant model Fresh full-thickness skin explants, 4 mm in diameter (surface area 12.5 mm 2 , weight 10-35 mg), were incubated for 15-24 hours (depending on the individual skin sample) with 500 ml of Williams' E medium containing 10 mM test substrate. Incubations were performed in duplicate. Metabolites were detected and quantified in both skin explant and corresponding medium. To calculate the activity rate for each donor, we divided the total amount of formed metabolite by the donor's average skin explant weight and specific incubation time (pmol·mg skin -1 ·h -1 ).
Metabolic Reaction
No. in fresh full-thickness skin explants (Fig. 1) . Since it contains all relevant cell types and has preserved skin morphology (Lebonvallet et al., 2010) , we selected this model and performed a proof-of-concept study to detect the activities of the five major phase II metabolism enzymes: UGTs, SULTs, NATs, COMT, and GSTs. Since phase I reactions may also significantly contribute to cutaneous biotransformation, activities of cytochrome P450s and other non-cytochrome P450 phase I enzymes in human skin explants need to be addressed in a separate study. To investigate interindividual variability, assays were performed with 17 skin donors in total, and each individual substrate was tested in a minimum of three donors. Combined with specific and sensitive bioanalytics (Table 4) , this study offered a unique advantage in detecting and quantifying novel metabolites formed in human skin. On the other hand, due to limited availability of fresh human skin, as well as the potential differences between extra-and intracellular concentrations of test compounds in skin explants (generally unsuitable for enzyme kinetic assays), incubations were limited to a single substrate concentration of 10 mM.
Results reveal that human skin explants metabolized all tested substrates ( Fig. 3; Table 6 ), indicating a potential for metabolic elimination and detoxification of diverse chemical structures. Activities measured for the same phase II reaction varied widely depending on the test substrate. As an example, glucuronidation rate was significantly higher for 4-methylumbelliferone compared with 17b-estradiol. Similar trends were observed for N-acetylation of p-toluidine (high) and procainamide (low), as well as for the sulfation of triclosan (high) and minoxidil (low). Rates of catechol methylation, for both 4-nitrocatechol and 2,3-dihydroxynaphthalene, and glutathione conjugation of 1-chloro-2,4-dinitrobenzene were generally high, especially during the first few hours of the incubation (Figs. 3 and 4) . Taken together, even if relative ranking of cutaneous reaction rates differ at different concentrations of test substrates, results suggest that considerable turnover may be expected under favorable conditions. Analysis of the substrates' physicochemical properties revealed that higher activity is generally favored for smaller and less polar substrates (Fig. 6) , possibly because these compounds are more likely to penetrate the skin cells. Although this analysis may indicate potential trends, cutaneous metabolism and permeation data for more compounds are needed to generate predictive models-for example, quantitative structure-activity relationships.
Interindividual variation of enzyme activities between skin donors was from 1.4-to 13.0-fold, depending on the test substrate, being highest for the 4-methylumbelliferone and diclofenac glucuronidation ( Table 6 ). Considering that skin donors were of different ages, ethnicities, genders, and lifestyles, and that skin samples from different anatomic regions were used (Table 3) , the observed cutaneous interindividual variability was moderately low, especially compared with variability Reactions were performed in duplicate. Incubation time was from 1 to 24 hours. Results are presented as the mean value and S.D. In addition to total metabolite formed (circles), each panel also presents metabolite quantified in either skin explants (squares) or corresponding incubation medium (triangles).
reported in hepatic glucuronidation (Court, 2010) , N-acetylation (Sim et al., 2008) , or glutathione conjugation (Temellini et al., 1995) . This finding may reflect one of the skin's principal physiologic roles as a robust barrier against xenobiotics. The sole exception is given by the male eyelid skin sample, which exhibited 3-fold above-average glucuronidation rates. Since a large majority of the skin donors were female (88%) and only a single eyelid skin sample was available, further research is needed to investigate whether differences in gender or anatomic region play a major role in cutaneous drug metabolism.
Glucuronidation rate was linear during 24 hours of incubation with skin explants, but rates of sulfation, N-acetylation, catechol methylation, and glutathione conjugation generally decelerated after 4 hours ( Fig. 4 ), suggesting that an enzyme kinetic assay should be performed with a shorter incubation time. Deviation from reaction rate linearity Table 5 .
Phase II Drug Metabolism in Skin Explants 135 at ASPET Journals on November 21, 2019 dmd.aspetjournals.org may generally arise from the depletion of substrate and cosubstrate, inhibition by the reaction products, or both, especially in the case of high-turnover reactions. Inclusion of cosubstrates for phase II enzymes, namely UDPGA, PAPS, AcCoA, and SAM, did not significantly modify the reaction rates (Fig. 5) , however, presumably because these highly polar molecules cannot easily penetrate the skin cells. On the other hand, accumulation of metabolites in the medium during the timecourse experiments (Fig. 4) , not the skin explants, suggested that phase II metabolites are actively excreted from the skin, diminishing the product inhibition within the cells. This hypothesis is supported by a recent finding that human skin expresses a number of ATP-binding cassette efflux transporters, particularly multidrug resistance-associated protein 1 (MRP1/ABCC1) (Osman-Ponchet et al., 2014) .
Rapid freezing of the human skin before incubations had a strongly negative effect on both metabolic activity, as measured by the 4-methylumbelliferone glucuronidation assay, and general skin explant viability (Fig. 7) . Even if some previous studies reported activities in microsomes prepared from frozen (Gotz et al., 2012) or cadaver human skin (Ademola et al., 1993) , the results presented here suggest that using fresh human skin is of high importance for drug metabolism studies. If the frozen full-thickness skin samples are used as an alternative to fresh tissue, further studies are needed to define the optimal and fully controlled freezing conditions, similar to ongoing efforts in preparing cryopreserved liver and kidney tissue slices [Fahy et al. (2013) and references therein].
Although few phase II biotransformation reactions were reported in the skin models previously (Table 2) Results are presented as the mean value and S.D. To prepare explants with skin after freezing, full-thickness skin from the same donor was snap-frozen in liquid N 2 , kept at -80°C for 7 days, and then thawed at room temperature. LOQ, lower limit of quantification; N.A., non-quantifiable amount of analyte. Fig. 8. (A) Comparison between intrinsic organ clearances predicted for human skin (CL int;skin ) and liver (CL int;liver ). (B) Fold difference between predicted CL int;liver and CL int;skin . Results are presented as the mean value 6 propagated S.D. error. CL int;liver was calculated based on enzyme kinetics parameters available from the literature ( Supplemental Table 1 ). 4-MU, 4-methylumbelliferone. (Gotz et al., 2012) , this study detected several novel metabolites. As an example, our study was the first to identify N-acetylprocainamide, as well as the methoxy derivatives of 4-nitrocatechol and 2,3dihydroxynaphthalene. Interestingly, we also found acyl glucuronides of indomethacin and diclofenac ( Fig. 3; Table 6 ), two nonsteroidal anti-inflammatory drugs that are commonly administered both topically and orally. Because acyl glucuronides may be chemically reactive (Regan et al., 2010; Boelsterli and Ramirez-Alcantara, 2011; Dickinson, 2011) , this finding has potential implications for skin toxicity, such as skin rash, an adverse effect observed for numerous therapeutic drugs (Mayorga et al., 2009; Chanprapaph et al., 2014) . A more recent study also reported that the formation of 12-hydroxynevirapine sulfate induced skin rash in rats (Sharma et al., 2013) . The present results revealed that minoxidil, triclosan, and 17b-estradiol are sulfated in human skin explants ( Fig. 3 ; Table 6 ). Appearance of acyl glucuronides and sulfates in the human skin explants suggests that even low metabolic rates may be relevant for pharmacotherapy and cosmetic research, if the formed metabolites are implicated in adverse drug reactions.
Since previous skin metabolism studies used different experimental models (e.g., split-thickness explants, cells, or subcellular fractions), a wide range of test substrate concentrations [e.g., 500 mM of 4-methylumbelliferone in Jäckh et al. (2011) versus 10 mM in the present study], or even different administration routes [topical triclosan in Moss et al. (2000) versus media inclusion in the present study], direct comparison of the measured activity rates is challenging. If substrate depletion only is taken into account (i.e., conversion rate percentage), our results on triclosan glucuronidation and sulfation correlate well with the values published previously (Moss et al., 2000) .
Comparison of the skin and liver organ clearances implies that skin contributes only marginally to total systemic phase II enzymemediated metabolic elimination in humans. Considering the significant lower intrinsic metabolic activities in skin and the fact that human skin flow is approximately 5-fold lower than the corresponding liver blood flow [300 vs. 1450 ml·min -1 for a 70-kg individual (Davies and Morris, 1993) ], this is not really surprising. However, it has to be noted here that, for the current assessment, a series of assumptions were made which underlie the high degree of uncertainty which accompanies this approach. For example, our efforts might be hampered by 1) lack of an appropriate physiologically based skin model, 2) possible permeability limitation of intrinsic clearance in skin explants, 3) high inherent variability of skin blood flow (Petrofsky, 2012) , 4) uncertainty of the drug's unbound fraction in skin, and 5) almost complete lack of suitable in vivo skin metabolism data for model validation. Besides that, current assessment exclusively focuses on the systemic elimination effect of skin metabolism. However, a cutaneous metabolic first-pass effect may significantly limit the bioavailability of topically and transdermally applied drugs (Zhang et al., 2009 ). However, the magnitude of the skin's first-pass effect, besides the specific enzymatic activities, will also depend on numerous factors such as the applied dose, administration surface area, skin thickness, drug partitioning, drug diffusion and permeability in the skin, potential active transport processes, local skin blood flow, and even metabolite diffusion coefficient in the skin (Boderke et al., 2000) . As a result of the aforementioned uncertainties, accurate predictions of both skin's total metabolic clearance and cutaneous first-pass effect need to be studied more in depth. The authors hope that the results in skin explants presented here will stimulate further research in the field of cutaneous drug metabolism, especially focusing on in vitro-in vivo correlations, first-pass effect, phase I metabolic reactions, and cross-validation of the available skin models.
In conclusion, results demonstrate that human skin has a significant potential for phase II metabolism through reactions of glucuronidation, sulfation, N-acetylation, catechol methylation, and glutathione conjugation. Even if the skin's capacity for phase II biotransformation appears low compared with the liver, cutaneous metabolism remains a relevant process for topical and transdermal drug administration, cosmetics, the study of adverse drug reactions in the skin, as well as for all drugs that are administrated systemically but targeted for dermal indications. Moreover, full-thickness human skin explants are an appropriate experimental model to study these reactions, especially if identification of novel skin metabolites is needed. Although the primary role of phase II reactions is metabolic elimination and detoxification, formation of acyl glucuronides and sulfates may contribute to the skin toxicity. As shown by several examples, reaction rates may be high, depending on the chemical structure of the drug and expression levels of the individual metabolic enzymes. These findings suggest that skin metabolism should be considered during drug and cosmetics development. 
